These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 23303810)

  • 21. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
    J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered heterochromatin organization after perinatal exposure to zidovudine.
    Senda S; Blanche S; Costagliola D; Cibert C; Nigon F; Firtion G; Floch C; Parat S; Viegas-Péquignot E
    Antivir Ther; 2007; 12(2):179-87. PubMed ID: 17503660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
    Stellbrink HJ; Orkin C; Arribas JR; Compston J; Gerstoft J; Van Wijngaerden E; Lazzarin A; Rizzardini G; Sprenger HG; Lambert J; Sture G; Leather D; Hughes S; Zucchi P; Pearce H;
    Clin Infect Dis; 2010 Oct; 51(8):963-72. PubMed ID: 20828304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults.
    Montejano R; Stella-Ascariz N; Monge S; Bernardino JI; Pérez-Valero I; Montes ML; Valencia E; Martín-Carbonero L; Moreno V; González-Garcia J; Rodriguez-Centeno J; Rodes B; Cantos AE; Alejos B; de Miguel R; Arnalich F; Perona R; Arribas JR
    J Infect Dis; 2018 Oct; 218(10):1531-1540. PubMed ID: 29912427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.
    De Pablo C; Orden S; Calatayud S; Martí-Cabrera M; Esplugues JV; Alvarez A
    Antivir Ther; 2012; 17(8):1615-9. PubMed ID: 22954798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thymidine analogue-sparing highly active antiretroviral therapy (HAART).
    Nolan D; Mallal S
    J HIV Ther; 2003 Feb; 8(1):2-6. PubMed ID: 12840707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
    Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
    Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
    Ray AS; Myrick F; Vela JE; Olson LY; Eisenberg EJ; Borroto-Esodo K; Miller MD; Fridland A
    Antivir Ther; 2005; 10(3):451-7. PubMed ID: 15918336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
    AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.
    Pace CS; Martin AM; Hammond EL; Mamotte CD; Nolan DA; Mallal SA
    Antivir Ther; 2003 Aug; 8(4):323-31. PubMed ID: 14518702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
    Curran A; Martinez E; Podzamczer D; Lonca M; Barragan P; Crespo M; Falco V; Vidal-Sicart S; Imaz A; Martinez M; Gatell JM; Ribera E
    Antivir Ther; 2012; 17(4):711-8. PubMed ID: 22374987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
    Breton G; Alexandre M; Duval X; Prie D; Peytavin G; Leport C; Vildei JL
    Scand J Infect Dis; 2004; 36(6-7):527-8. PubMed ID: 15307594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
    Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
    Venhoff N; Setzer B; Melkaoui K; Walker UA
    Antivir Ther; 2007; 12(7):1075-85. PubMed ID: 18018766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.
    Miura T; Goto M; Hosoya N; Odawara T; Kitamura Y; Nakamura T; Iwamoto A
    J Med Virol; 2003 Aug; 70(4):497-505. PubMed ID: 12794710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
    Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
    AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients.
    Montejano R; Stella-Ascariz N; Monge S; Bernardino JI; Pérez-Valero I; Montes ML; Valencia E; Martín-Carbonero L; Moreno V; González-García J; Arnalich F; Mingorance J; Pintado Berniches L; Perona R; Arribas JR
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):102-109. PubMed ID: 28418989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.